Our pan-cancer analysis of TCGA data revealed consistent and significant SMYD2 upregulation across multiple malignancies including GC, breast cancer, colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer (Figures 3B, C), validating and extending prior reports (16, 43–45). Here, SMYD2 is linked to prostate carcinoma.